BioMarin Pharma (BMRN) Announces MHRA in UK Approves Continued Enrollment in 1/2 Study of BMN 270 in Hemophilia A
Go back to BioMarin Pharma (BMRN) Announces MHRA in UK Approves Continued Enrollment in 1/2 Study of BMN 270 in Hemophilia A| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 90.07 -0.4 (0.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.47 | 52 Week High | $108.96 | |||
| Open | $90.25 | 52 Week Low | $62.12 | |||
| Day High | $91.21 | P/E | N/A | |||
| Day Low | $89.78 | EPS | $-1.27 | |||
| Volume | 944,850 | |||||
